Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFI-400945 in Advanced/Metastatic Breast Cancer
NCT03624543Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Feb 2019
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ocifisertib in breast cancer (3 cohorts), sponsored by Canadian Cancer Trials Group. Primary endpoint: Objective Response Rate at 2 years. Started Feb 2019; status: active, not recruiting.
02
Drugs
ocifisertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03624543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624543.